Matinas BioPharma Stock Forecast, Price & News

-0.03 (-3.38 %)
(As of 06/15/2021 11:05 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume34,630 shs
Average Volume952,808 shs
Market Capitalization$175.68 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Matinas BioPharma logo

About Matinas BioPharma

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.36 out of 5 stars

Medical Sector

794th out of 2,100 stocks

Pharmaceutical Preparations Industry

391st out of 832 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

Is Matinas BioPharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Matinas BioPharma stock.
View analyst ratings for Matinas BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than Matinas BioPharma?

Wall Street analysts have given Matinas BioPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Matinas BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Matinas BioPharma

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Monday, May, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.03).
View Matinas BioPharma's earnings history

What price target have analysts set for MTNB?

4 analysts have issued twelve-month price objectives for Matinas BioPharma's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Matinas BioPharma's stock price to reach $3.38 in the next year. This suggests a possible upside of 275.0% from the stock's current price.
View analysts' price targets for Matinas BioPharma
or view top-rated stocks among Wall Street analysts.

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the following people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 47, Pay $750k)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 54, Pay $490k)
  • Dr. James J. Ferguson, Chief Medical Officer (Age 67, Pay $560k)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 51)
  • Dr. Hui Liu M.B.A., Ph.D., Chief Technology Officer (Age 54)
  • Dr. Raphael J. Mannino, Chief Scientific Officer (Age 74)
  • Ian Cooney, Director of Investor Relations & Corp. Devel.
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain

Who are some of Matinas BioPharma's key competitors?

What other stocks do shareholders of Matinas BioPharma own?

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.55%), Sargent Investment Group LLC (0.98%), Geode Capital Management LLC (0.62%), Victory Capital Management Inc. (0.48%), Royal Bank of Canada (0.38%) and HRT Financial LP (0.36%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Jerome D Jabbour, Keith A Kucinski and Patrick G Lepore.
View institutional ownership trends for Matinas BioPharma

Which major investors are selling Matinas BioPharma stock?

MTNB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Victory Capital Management Inc., Royal Bank of Canada, and Bank of New York Mellon Corp.
View insider buying and selling activity for Matinas BioPharma
or view top insider-selling stocks.

Which major investors are buying Matinas BioPharma stock?

MTNB stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., HRT Financial LP, Sargent Investment Group LLC, Squarepoint Ops LLC, Citadel Advisors LLC, Price T Rowe Associates Inc. MD, Geode Capital Management LLC, and MYDA Advisors LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, Jerome D Jabbour, Keith A Kucinski, and Patrick G Lepore.
View insider buying and selling activity for Matinas BioPharma
or or view top insider-buying stocks.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.90.

How much money does Matinas BioPharma make?

Matinas BioPharma has a market capitalization of $183.85 million and generates $160,000.00 in revenue each year. The company earns $-22,450,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Matinas BioPharma have?

Matinas BioPharma employs 20 workers across the globe.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is www.matinasbiopharma.com.

Where are Matinas BioPharma's headquarters?

Matinas BioPharma is headquartered at SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.